Nevertheless, ARO-PNPLA3, a prospective therapeutic agent for MASLD, is still unknown for the effect of PNPLA3 inhibition on urate and gout. The gene discussed is CYP19A1; the disease is metabolic dysfunction-associated steatotic liver disease.